161 related articles for article (PubMed ID: 28912087)
1. Endocannabinoid mechanism in amphetamine-type stimulant use disorders: A short review.
Su H; Zhao M
J Clin Neurosci; 2017 Dec; 46():9-12. PubMed ID: 28912087
[TBL] [Abstract][Full Text] [Related]
2. Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction.
Cao DN; Shi JJ; Hao W; Wu N; Li J
Eur J Pharmacol; 2016 Jun; 780():129-35. PubMed ID: 27018393
[TBL] [Abstract][Full Text] [Related]
3. The role of the GABA system in amphetamine-type stimulant use disorders.
Jiao D; Liu Y; Li X; Liu J; Zhao M
Front Cell Neurosci; 2015; 9():162. PubMed ID: 25999814
[TBL] [Abstract][Full Text] [Related]
4. New perspectives in the studies on endocannabinoid and cannabis: a role for the endocannabinoid-arachidonic acid pathway in drug reward and long-lasting relapse to drug taking.
Yamamoto T; Anggadiredja K; Hiranita T
J Pharmacol Sci; 2004 Dec; 96(4):382-8. PubMed ID: 15599102
[TBL] [Abstract][Full Text] [Related]
5. The role of CB1 receptors in psychostimulant addiction.
Wiskerke J; Pattij T; Schoffelmeer AN; De Vries TJ
Addict Biol; 2008 Jun; 13(2):225-38. PubMed ID: 18482432
[TBL] [Abstract][Full Text] [Related]
6. Endocannabinoids and striatal function: implications for addiction-related behaviours.
Moreira FA; Jupp B; Belin D; Dalley JW
Behav Pharmacol; 2015 Feb; 26(1-2):59-72. PubMed ID: 25369747
[TBL] [Abstract][Full Text] [Related]
7. Clinical neuroscience of amphetamine-type stimulants: From basic science to treatment development.
Courtney KE; Ray LA
Prog Brain Res; 2016; 223():295-310. PubMed ID: 26806782
[TBL] [Abstract][Full Text] [Related]
8. Endocannabinoid system as a therapeutic target for psychostimulants relapse: A systematic review of preclinical studies.
Karimi-Haghighi S; Mahmoudi M; Sayehmiri F; Mozafari R; Haghparast A
Eur J Pharmacol; 2023 Jul; 951():175669. PubMed ID: 36965745
[TBL] [Abstract][Full Text] [Related]
9. The role of the endogenous cannabinoid system in drug addiction.
Parolaro D; Rubino T
Drug News Perspect; 2008 Apr; 21(3):149-57. PubMed ID: 18560613
[TBL] [Abstract][Full Text] [Related]
10. Does chronic use of amphetamine-type stimulants impair interference control? - A meta-analysis.
Opitz A; Petasch MS; Klappauf R; Kirschgens J; Hinz J; Dittmann L; Dathe AS; Quednow BB; Beste C; Stock AK
Neurosci Biobehav Rev; 2023 Mar; 146():105020. PubMed ID: 36581170
[TBL] [Abstract][Full Text] [Related]
11. Brain event-related potentials associated with psychiatric symptoms in amphetamine-type stimulant dependent patients.
Zhang Y; Zhong BL; Li Y; Ma ZL; Tian Y; Tang J
Int J Psychiatry Med; 2012; 43(2):189-96. PubMed ID: 22849040
[TBL] [Abstract][Full Text] [Related]
12. Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China.
Zhang Y; Lu C; Zhang J; Hu L; Song H; Li J; Kang L
Addict Behav; 2013 Jan; 38(1):1424-30. PubMed ID: 23006246
[TBL] [Abstract][Full Text] [Related]
13. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization.
Thiemann G; van der Stelt M; Petrosino S; Molleman A; Di Marzo V; Hasenöhrl RU
Behav Brain Res; 2008 Mar; 187(2):289-96. PubMed ID: 17988751
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade.
Anggadiredja K; Nakamichi M; Hiranita T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Neuropsychopharmacology; 2004 Aug; 29(8):1470-8. PubMed ID: 15085091
[TBL] [Abstract][Full Text] [Related]
15. The endocannabinoid system and psychiatric disorders.
Parolaro D; Realini N; Vigano D; Guidali C; Rubino T
Exp Neurol; 2010 Jul; 224(1):3-14. PubMed ID: 20353783
[TBL] [Abstract][Full Text] [Related]
16. Early Initiation of Amphetamine-Type Stimulants (ATS) Use Associated with Lowered Cognitive Performance among Individuals with Co-Occurring Opioid and ATS Use Disorders in Malaysia.
Chooi WT; Mohd Zaharim N; Desrosiers A; Ahmad I; Yasin MAM; Syed Jaapar SZ; Schottenfeld RS; Vicknasingam BK; Chawarski MC
J Psychoactive Drugs; 2017; 49(4):326-332. PubMed ID: 28661714
[TBL] [Abstract][Full Text] [Related]
17. Impulsivity, Stimulant Abuse, and Dopamine Receptor Signaling.
London ED
Adv Pharmacol; 2016; 76():67-84. PubMed ID: 27288074
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the endocannabinoid system in drug addiction.
Maldonado R; Valverde O; Berrendero F
Trends Neurosci; 2006 Apr; 29(4):225-32. PubMed ID: 16483675
[TBL] [Abstract][Full Text] [Related]
19. Endocannabinoid regulation of relapse mechanisms.
Fattore L; Fadda P; Fratta W
Pharmacol Res; 2007 Nov; 56(5):418-27. PubMed ID: 17936008
[TBL] [Abstract][Full Text] [Related]
20. The endocannabinoid system: physiology and pharmacology.
RodrÃguez de Fonseca F; Del Arco I; Bermudez-Silva FJ; Bilbao A; Cippitelli A; Navarro M
Alcohol Alcohol; 2005; 40(1):2-14. PubMed ID: 15550444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
